Newsletter | January 16, 2024

01.16.24 -- A Patient-Centric Approach Built On The Porosome


A Patient-Centric Approach Built On The Porosome

About 85% of disease-causing proteins remain impervious to current therapeutic interventions. One potential pathway to address this problem: the porosome.

Pacesetters Are Product Innovators Who Embrace Digital Process Enhancement

The Josh Bersin Company recently underwent research examining pharma/biotech “pacesetters” in the field. We caught up with Jordan Schmitting, senior research analyst at The Josh Bersin Company, to discuss the trends illuminated by the research.


Rapid Development Of Amorphous Solid Dispersions For Bioavailability

See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.

Empowering A New Era Of Patient-Centric Medicines

Discover the challenges pharma companies are facing as they switch focus as well as the actions and technologies companies are implementing to help achieve a brighter future for patients.

Solving The Analytics Bottleneck In Cell Line Development

Discover a fully automated, benchtop, walk-away system for accelerated and efficient cell culture sample preparation. Learn how this system clarifies and purifies mAbs in one step without sacrificing quality.

Predictive Modeling Of Concentration-Dependent Viscosity Behavior

Review a modeling approach employing artificial neural networks using experimental factors combined with simulation-derived parameters plus viscosity data from 27 highly concentrated mAbs.


Participate In BioPlan’s 21st Annual Biopharma Manufacturing Study!

Ensure your voice is included in the bioindustry's most authoritative, comprehensive analysis! Be the first to receive this year's industry benchmarking, and more! For each completed survey, BioPlan will either send a $35 Amazon e-gift card or donate up to $3,000 to global health charities. Participate now.


Bifrost Biosystems Launches With Novel Optical Pooled Screening Technology

Nimbus Therapeutics Announces Expansion Of Its Immunology Drug Discovery Pipeline

Johnson & Johnson To Acquire Ambrx

Accenture Invests In QuantHealth To Accel Use Of AI-Powered Clinical Trial Simulations

Nuvation Bio Announces FDA Clearance Of IND Application For NUV-1511

U.S. FDA Approves ZELSUVMI As A First-In-Class Medication

New NIH-Funded Center Could Soon Reduce The Need For Pharm Trials On Animals

Servier And Base4 Expand Partnership To Advance Neuroscience Drug Development

Deloitte Expands Quartz AI Suite With Atlas AI For Drug Discovery

Iktos & Nerviano Medical Sciences S.r.l Announce Collaboration In AI

Corbus Pharmaceuticals Announces FDA Clearance Of IND Application


Solid Form Services

High Performance, Reliable, And Flexible Bioreactors